Mark Titus
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
S1. Seahorse assays on C4-2B and PC3 cells cultured in 2D. S2. Seahorse assays on C4-2B and PC3 cells cultured in 2D and treated with IACS-10759. S3. Luciferase assay and crystal violet staining are comparable methods for monitoring PCa cells growth. S4. Representative pictures of tumor-free, PC3 tumor-bearing control and PC3 tumor-bearing IACS-10759 treated tibiae.
Year:
2025
Aberrant metabolic functions play a crucial role in prostate cancer progression and lethality. Currently, limited knowledge is available on subtype-specific metabolic features and their implications for treatment. We therefore investigated the metabolic determinants of the two major subtypes of castration-resistant prostate cancer [androgen receptor–expressing prostate cancer (ARPC) and aggressive variant prostate cancer (AVPC)]. Transcriptomic analyses revealed enrichment of gene sets involved in oxidative phosphorylation (OXPHOS) in ARPC tumor samples compared with AVPC. Unbiased screening of metabolic signaling pathways in patient-derived xenograft models by proteomic analyses further supported an enrichment of OXPHOS in ARPC compared with AVPC, and a skewing toward glycolysis by AVPC. In vitro , ARPC C4–2B cells depended on aerobic respiration, while AVPC PC3 cells relied more heavily on glycolysis, as further confirmed by pharmacologic interference using IACS-10759, a clinical-grade inhibitor of OXPHOS. In vivo studies confirmed IACS-10759′s inhibitory effects in subcutaneous and bone-localized C4–2B tumors, and no effect in subcutaneous PC3 tumors. Unexpectedly, IACS-10759 inhibited PC3 tumor growth in bone, indicating microenvironment-induced metabolic reprogramming. These results suggest that castration-resistant ARPC and AVPC exhibit different metabolic dependencies, which can further undergo metabolic reprogramming in bone. Implications: These vulnerabilities may be exploited with mechanistically novel treatments, such as those targeting OXPHOS alone or possibly in combination with existing therapies. In addition, our findings underscore the impact of the tumor microenvironment in reprogramming prostate cancer metabolism.
Year:
2025
Year:
2023
Year:
2023
Collaborators (8)
Taran Gujral
Professor
Fred Hutchinson Cancer Research Center
Daniel Frigo
Scientific Director of Research
The University of Texas MD Anderson Cancer Center
Christopher J. Logothetis
The University of Texas MD Anderson Cancer Center
Sue-Hwa Lin
Professor
The University of Texas MD Anderson Cancer Center
Eleonora Dondossola
The University of Texas MD Anderson Cancer Center
Paul Corn
Chair
The University of Texas MD Anderson Cancer Center
Daniele Robesti
Vita-Salute San Raffaele University
Eva Corey
Professor
University of Washington
Make your next move.
Prepare your application
Review drafts before you send them.